Thomas J. Dietz's most recent trade in Cypherpunk Technologies Inc. was a trade of 104,500 Restricted Stock Units done . Disclosure was reported to the exchange on March 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 104,500 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2026 | 104,500 | 152,500 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2025 | 104,500 | 104,500 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2025 | 83,000 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2025 | 83,000 | 83,000 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.20 per share. | 23 Dec 2025 | 35,000 | 48,000 (0%) | 0% | 1.2 | 42,000 | Common Stock |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2025 | 83,000 | 83,000 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | J. Thomas Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 17,500 | 17,500 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 175,000 | 175,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2023 | 20,000 | 70,000 (0%) | 0% | 0 | Common Stock | |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Purchase of securities on an exchange or from another person at price $ 1.43 per share. | 23 Jan 2023 | 50,000 | 50,000 (0%) | 0% | 1.4 | 71,580 | Common Stock |
| Eiger BioPharmaceuticals Inc | Thomas J. Dietz | Director | Sale of securities on an exchange or to another person at price $ 1.17 per share. | 22 Dec 2022 | 22,500 | 21,000 (0%) | 0% | 1.2 | 26,303 | Common Stock |
| Paratek Pharmaceuticals Inc. | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 20,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Leap Therapeutics Inc | Thomas J. Dietz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) |